Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease

2021/01/22 by Cynthia Kwan, Imane Frouni, Stephen G. Nuara +8 · 7 citations
Neuroscience · Medicine · #Neuroscience and Neuropharmacology Research #Neurotransmitter Receptor Influence on Behavior #Neurological disorders and treatments

paper · doi:10.1016/j.neuropharm.2021.108465

Citations

• Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey
• Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism

Cited by

• Structural Characterization of Receptor-Receptor Interactions in the Allosteric Modulation of G Protein-Coupled Receptor (GPCR) Dimers. [europepmc]
• Preclinical Marmoset Model for Targeting Chronic Inflammation as a Strategy to Prevent Alzheimer's Disease. [europepmc]
• Research Progress on the Pharmacological Action of Schisantherin A. [europepmc]
• The effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson's disease. [europepmc]
• Global research trends and hotspots in Parkinson's disease psychosis: a 25-year bibliometric and visual analysis. [europepmc]
• The Dual Role of A2aR in Neuroinflammation: Modulating Microglial Polarization in White Matter Lesions. [europepmc]
• Allosteric activation of the glutamate receptor mGlu2 by the serotonin receptor 5-HT 2A . [europepmc]